换一批
换一批Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.
作者：
主题词
老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤(Breast Neoplasms);化学疗法, 辅助(Chemotherapy, Adjuvant);表柔比星(Epirubicin);可行性研究(Feasibility Studies);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);免疫酶技术(Immunoenzyme Techniques);肿瘤复发, 局部(Neoplasm Recurrence, Local);肿瘤分期(Neoplasm Staging);紫杉酚(Paclitaxel);前瞻性研究(Prospective Studies);受体, 雌激素(Receptors, Estrogen);受体, 孕酮(Receptors, Progesterone);存活率(Survival Rate);治疗结果(Treatment Outcome)
DOI
10.1016/j.clbc.2011.06.002
PMID
21737355
发布时间
2015-11-19
- 浏览24
Clinical breast cancer
235-40页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
